Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats Varsha GandhiWei ChenRobert A. Newman Original Article Pages: 85 - 94
Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug Laurence Kraus-BerthierNicolas GuilbaudAlain Pierré Original Article Pages: 95 - 103
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer Jin-Hee AhnYoon-Koo KangJung-Sik Park Original Article Pages: 104 - 110
Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs Peter D. ColeAngela K. SmithBarton A. Kamen Original Article Pages: 111 - 116
Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study Birgitte Klug AlbertsenKjeld SchmiegelowPreben Jakobsen Original Article Pages: 117 - 120
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment Chetan LathiaGini F. FlemingLloyd Whitfield Original Article Pages: 121 - 126
Bcl2-negative MCF7 cells overexpress p53: implications for the cell cycle and sensitivity to cytotoxic drugs Laura PolisenoLaura MarianiGiuseppe Rainaldi Original Article Pages: 127 - 130
STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial David M. VailIlene D. KurzmanPeter K. Working Original Article Pages: 131 - 136
Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer Ritsu YamamotoMasanori KaneuchiTakeshi Hirano Original Article Pages: 137 - 142
Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells Tamara MinkoPankaj V. ParanjpePatrick J. Sinko Original Article Pages: 143 - 150
A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study Steven C. PlaxeJohn A. BlessingFidel A. Valea Original Article Pages: 151 - 154
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer Catharina WenzelGottfried J. LockerGuenther G. Steger Original Article Pages: 155 - 159
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer D. Park C. Ryan W. Stadler Clinical Trial Report Pages: 160 - 162
The chemokine CCL21 protects normal marrow progenitors from Ara-C cytotoxicity Robert HromasScott CooperHal E. Broxmeyer Short Communication Pages: 163 - 166
c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571) Marc HotfilderClaudia LanversJosef Vormoor Short Communication Pages: 167 - 169